Search

Displaying results 1831 - 1840 of 6835 in total
  1. Drug

    Dexamethasone

    go.drugbank.com/drugs/DB01234
    ApprovedInvestigationalVet approved

    Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318] … [L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.

    Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UD
  2. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA

  3. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908]

  4. Drug

    Ezetimibe

    go.drugbank.com/drugs/DB00973
    ApprovedInvestigational

    [A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.[L11347] … [A15202] Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous

  5. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. … [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

  6. Drug

    Tropisetron

    go.drugbank.com/drugs/DB11699
    ApprovedInvestigationalWithdrawn

    Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal side effects are rare upon using tropisetron.

  7. Drug

    Aminohippuric acid

    go.drugbank.com/drugs/DB00345
    ApprovedInvestigationalWithdrawn

    Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

  8. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

  9. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190486] The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.[L11575] … [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.

  10. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    [A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827] … Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery